Literature DB >> 9165691

Optimizing the intragastric pH as a supportive therapy in upper GI bleeding.

G Brunner1, P Luna, M Hartmann, W Wurst.   

Abstract

Acid inhibitory therapy has long been considered of no benefit for upper GI bleeding. The reason was that achlorhydria in the stomach could not be achieved with any single or combination of acid inhibitory drugs. The introduction of proton pump inhibitors has, for the first time, allowed the physician to temporarily achieve achlorhydria by large doses of intravenously applied proton pump inhibitors. The first placebo-controlled clinical trials have shown that, indeed, an intragastric pH of near 7 can significantly improve the clinical outcome of upper GI bleeding. Pharmacokinetic studies with proton pump inhibitors have shown that a bolus of 80 mg pantoprazole or omeprazole followed by immediate continuous infusion of eight mg per hour will result in an intragastric pH of 7 within 20 minutes. This intragastric pH optimizes the different steps of hemostasis in the stomach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9165691      PMCID: PMC2589014     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  24 in total

1.  Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial.

Authors:  G Brunner; J Chang
Journal:  Digestion       Date:  1990       Impact factor: 3.216

Review 2.  Endoscopic haemostasis for non-variceal upper gastrointestinal haemorrhage.

Authors:  R J Steele
Journal:  Br J Surg       Date:  1989-03       Impact factor: 6.939

Review 3.  Drugs for pH control in upper gastrointestinal bleeding.

Authors:  G Brunner; P Luna; C Thiesemann
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

4.  Two endothelin receptors (ETA and ETB) expressed on circular smooth muscle cells of guinea pig cecum.

Authors:  H Okabe; Y Chijiiwa; K Nakamura; M Yoshinaga; H Akiho; N Harada; H Nawata
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

5.  Pharmacodynamics of intravenous ranitidine after bolus and continuous infusion in patients with healed duodenal ulcers.

Authors:  S W Sanders; K N Buchi; J G Moore; A L Bishop
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

6.  Continuous intravenous famotidine for haemorrhage from peptic ulcer.

Authors:  R P Walt; J Cottrell; S G Mann; N P Freemantle; M J Langman
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

7.  Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?

Authors:  H S Merki; C H Wilder-Smith
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

8.  [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison].

Authors:  J Busam; W E Garbe
Journal:  Z Gastroenterol       Date:  1994-02       Impact factor: 2.000

9.  The potential clinical role of intravenous omeprazole.

Authors:  G H Brunner; C Thiesemann
Journal:  Digestion       Date:  1992       Impact factor: 3.216

10.  Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial.

Authors:  T K Daneshmend; C J Hawkey; M J Langman; R F Logan; R G Long; R P Walt
Journal:  BMJ       Date:  1992-01-18
View more
  16 in total

1.  A novel placement method of the Bravo wireless pH monitoring capsule for measuring intragastric pH.

Authors:  Jae Hyuck Chang; Myung Gyu Choi; Dong-Seok Yim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Sang Woo Kim; In Sik Chung
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

Review 2.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy.

Authors:  Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Su Bum Park; Kee Tae Park; Gwang Ha Kim; Geun Am Song; Mong Cho
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

Review 4.  Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer.

Authors:  Venodhar R Julapalli; David Y Graham
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 5.  Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding.

Authors:  Grigoris I Leontiadis; Virender K Sharma; Colin W Howden
Journal:  BMJ       Date:  2005-01-31

6.  Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers.

Authors:  Ping-I Hsu; Gin-Ho Lo; Ching-Chu Lo; Chiun-Ku Lin; Hoi-Hung Chan; Chung-Jen Wu; Chang-Bih Shie; Pei-Min Tsai; Deng-Chyang Wu; Wen-Ming Wang; Kwok-Hung Lai
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

Review 7.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Pharmacologic treatment of peptic ulcer bleeding.

Authors:  Grigoris I Leontiadis; Colin W Howden
Journal:  Curr Treat Options Gastroenterol       Date:  2007-04

Review 9.  Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding.

Authors:  Jun Wang; Kehu Yang; Bin Ma; Jinhui Tian; Yali Liu; Zhenggang Bai; Lei Jiang; Shaoliang Sun; Jun Li; Ruifeng Liu; Xiangyong Hao; Xiaodong He
Journal:  Can J Gastroenterol       Date:  2009-04       Impact factor: 3.522

Review 10.  Intravenous proton pump inhibitors: an evidence-based review of their use in gastrointestinal disorders.

Authors:  Marc Bardou; Janet Martin; Alan Barkun
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.